generation-prostate-cancer-cell-models-resistance-to-anti-mitotic

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Microtubule targeting agents (MTAs) are a mainstay in the treatment of a wide range of tumors. However, acquired resistance to chemotherapeutic drugs is a ...

Icahn School of Medicine at Mount Sinai

Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.

Marc Carceles-Cordon

Department of Pathology,
Tisch Cancer Institute,
Department of Pathology, Tisch Cancer Institute

Icahn School of Medicine at Mount Sinai

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Marc Carceles-Cordon

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Pathology,Tisch Cancer Institute,Department of Pathology, Tisch Cancer Institute

Icahn School of Medicine at Mount Sinai

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Department of Pathology,
Tisch Cancer Institute,
Department of Pathology, Tisch Cancer Institute